This content is not available in your region

Novartis CEO says no decision has been taken on Sandoz

Novartis CEO says no decision has been taken on Sandoz
Novartis CEO says no decision has been taken on Sandoz   -   Copyright  Thomson Reuters 2022
By Reuters

ZURICH – Novartis has not decided what to do with its Sandoz generics unit after announcing a strategic review of the business last year, its chief executive said on Monday.

“No decision has been taken on Sandoz, we continue to evaluate the options,” Vas Narasimhan said at the J.P. Morgan Healthcare conference. He also said the Swiss drugmaker continued to look for value-creating bolt-on acquisitions.